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Exercise and pharmacologic stress echocardio-
graphy have been used routinely in clinical practi-
ce for the past twenty to thirty years [1–3]. Over
this time, stress echocardiography has become an
accepted means of evaluation for perfusion-limiting
coronary artery obstruction, and for assessing risk.
Historically, based on meta-analyses, the sensiti-
vity and specificity have been reported to be appro-
ximately 80% [4, 5]. However, it has been traditio-
nally held that exercise stress testing is superior
to pharmacologic stress testing due to a more “phy-
siologic” effect with exercise.
A limitation of any exercise stress testing mo-
dality has been that patients must achieve a target
heart rate of 85% of their maximal predicted heart
rate (calculated as 220 – patient’s age) for the stu-
dy to be considered “diagnostic” [6]. Recent data
have challenged traditional thinking by demonstra-
ting superiority of the dobutamine stress protocol
over standard exercise stress echocardiography,
with a nearly four-fold higher likelihood of achie-
ving target heart rate [7]. Given the increase in the
number of patients on rate-lowering beta and cal-
cium channel blocking agents, especially amongst
those with known ischemic heart disease, the dia-
gnostic utility of stress testing has become an im-
portant issue. Since these medications are more
likely to blunt the chronotropic response, yielding
submaximal heart rates, studies may often be ren-
dered inconclusive.
Among patients not on heart rate lowering
agents, the rate of failure to reach at least 85% of
the maximal predicted heart rate is 15–25% [8].
Amongst those on beta-blockers, the reported in-
cidence of failure reaches 30–50% [9, 10]. The
inability to reach target heart rate has been termed
“chronotropic incompetence”, and is predictive of
cardiac death, independent of abnormalities on
stress testing or other comorbid illnesses [8]. The
administration of atropine has become a common
component of pharmacologic stress protocols in
order to overcome submaximal stress, and help
patients achieve target heart rates [10]. While the
use of atropine has been demonstrated to increase
the overall sensitivity of dobutamine stress echo-
cardiography (DSE), it is achieved at the expense
of other useful information such as heart rate reco-
very and the presence of chronotropic incompeten-
ce [8, 10]. These findings have great prognostic
implications; thus, while a useful tool to improve
heart rate response and demonstrate wall motion ab-
normalities on echocardiography at peak stress, key
information may be lost with the use of atropine.
The true diagnostic utility of submaximal stress
testing, particularly in patients on heart rate lowe-
ring agents, has not been well studied and is not well
understood [11]. Although there is evidence that
dobutamine may be more efficacious in helping pa-
tients to achieve target heart rates [7], there is still
considerable controversy as to the predictive value
of these tests if maximal predicted heart rate is not
attained. In this edition of the “Cardiology Journal”,
Patel et al. [12] attempt to answer this question by
presenting an interesting study examining the pro-
gnostic capability of DSE with submaximal heart
rate response. The study looks retrospectively at
756 patients with negative DSE testing, divided into
two groups based on the achievement or failure to
achieve a maximal predicted heart rate ≥ 85%. Not
surprisingly, beta-blocker and calcium channel bloc-
ker usage was higher in the group that did not achie-
ve target heart rate. The striking finding in this study
is that the traditional combined outcome of cardiac
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death, nonfatal myocardial infarction, and revascu-
larization was not significantly different between
those who had submaximal heart rate thresholds,
and those who achieved a maximal heart rate re-
sponse after a mean of 36 months of follow up. The
authors report a three year event-free survival of
98% in both groups.
The study seems to suggest that negative sub-
maximal DSE may be an acceptable predictor of
future risk, particularly in patients on nodal bloc-
king agents. The one caveat to this finding is dia-
betes, which on multivariate analysis was found to
be a significant predictor of any cardiac event. Exa-
mining the study more closely, the relative youth
of the submaximal heart rate group (69.4 ± 12.9 vs.
73 ± 11.1 years of age, p < 0.0001) is a confoun-
ding variable that may confer an event-free survi-
val benefit. However, this group also had a higher
incidence of prior PCI (with a notable trend towards
an increase in prior myocardial infarction, p = 0.08),
hypertension, history of heart failure, and diabetes,
all of which would be expected to increase the num-
ber of adverse cardiac events. In any case, the other
important factor that must be considered when in-
terpreting the study is that more than 80% of the
patients had a normal left ventricular ejection fraction;
which speaks to the overall health of the group. Whe-
ther or not the results would be reproducible in
a group with underlying resting systolic dysfunc-
tion is unknown, and certainly, future studies exa-
mining this subgroup would be useful.
The current study by Patel et al. [12] builds
upon a previous study by Labib et al. [13] from 2004
which demonstrated non-differential cardiac event
rates among 429 patients with negative maximal and
submaximal DSE prior to non-cardiac surgery. Fur-
ther, Patel et al. [12] reaffirmed the finding that dia-
betic patients with a negative stress echocardio-
gram are at a significantly higher risk of cardiac
events than their non-diabetic counterparts, as pre-
viously shown by Kamalesh et al. [14] (19% inci-
dence of cardiac events amongst diabetics versus
9.7% amongst non-diabetics). Thus, one must still
use caution in taking reassurance in a negative
stress echocardiogram in this population.
In conclusion, DSE remains a clinically valid
and useful tool for stratifying patients’ future risk
of cardiac events. The study by Patel et al. [12] does
provide evidence for the prognostic utility of nega-
tive submaximal DSE, particularly amongst patients
on heart rate lowering medications. However,
interpretive restraint must be used amongst diabetic
patient’s as there is still a significant risk of adver-
se cardiac events in this population. Future studies
examining the usefulness of negative submaximal
DSE testing in patients with underlying systolic
dysfunction are needed, as the current study was
not intended to, and does not adequately assess, this
population.
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